Dose-Dependent Effects of Resveratrol on Cisplatin-Induced Hearing Loss.

Abstract

Previous preclinical studies have demonstrated the otoprotective effects of resveratrol (RV) at low doses. This study aimed to investigate the dose-dependent effects of RV in rats with cisplatin (CXP)-induced hearing loss. Sprague-Dawley rats (8-weeks old) were divided into six treatment groups (n = 12/group) and treated as follows: control, 0.5 mg/kg RV, 50 mg/kg RV, CXP, 0.5 mg/kg RV + CXP), and 50 mg/kg RV + CXP groups. CXP (3 mg/kg) was intraperitoneally injected for 5 days. RV (0.5 or 50 mg/kg) was intraperitoneally injected for 10 days from the first day of CXP administration. Auditory brainstem response (ABR) thresholds were measured before and within 3 days at the end of the drug administration. Cochlear tissues were harvested, and the outer hair cells were examined using cochlear whole mounts. The mRNA expression of NFκB, IL6, IL1β, and CYP1A1, and protein levels of aryl hydrocarbon receptor (AhR) and cytosolic and nuclear receptor for advanced glycation endproducts (RAGE) were evaluated. The ABR threshold increased in the 50 mg/kg RV and CXP groups at 4, 8, 16, and 32 kHz. The 0.5 mg/kg RV + CXP group demonstrated decreased hearing thresholds at 4 and 32 kHz compared to the CXP group. Cochlear whole-mount analysis revealed loss of outer hair cells in the 50 mg/kg RV and CXP groups and partial prevention of these cells in the 0.5 mg/kg RV + CXP group. The mRNA expressions of NFκB, IL6, and IL1β were increased in the 50 mg/kg RV and CXP groups compared to the control group. In contrast, these levels were decreased in the 0.5 mg/kg RV + CXP group compared to the CXP group. The mRNA expression of CYP1A1 was increased in the CXP group, while it was decreased in the 0.5 mg/kg RV + CXP group compared to the control group. The protein levels of AhR and cytosolic RAGE decreased in the 0.5 mg/kg RV group. Low-dose RV had partial otoprotective effects on CXP ototoxicity. The otoprotective effects of RV may be mediated through anti-oxidative (CYP1A1 and RAGE) and anti-inflammatory (NFκB, IL6, and IL1β) responses. High-dose RV exerted an inflammatory response and did not ameliorate CXP-induced ototoxicity.

• Authors: Chang Ho Lee, Kyung Woon Kim, So Min Lee, So Young Kim
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 22 Issue 1 (Dec 24 2020) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 33374326 (Publication Type: Journal Article)

Chemical References

• Antioxidants
• IL1B protein, rat
• Il6 protein, rat
• Interleukin-1beta
• Interleukin-6
• NF-kappa B p50 Subunit
• RNA, Messenger
• Receptors, Aryl Hydrocarbon
• Cytochrome P-450 CYP1A1
• Cisplatin
• Resveratrol

Topics

• Animals
• Antioxidants (pharmacology)
• Cisplatin (adverse effects)
• Cochlea (drug effects)
• Cytochrome P-450 CYP1A1 (biosynthesis)
• Dose-Response Relationship, Drug
• Evoked Potentials, Auditory, Brain Stem (drug effects)
• Female
• Hearing Loss, Sensorineural (chemically induced, drug therapy)
• Inflammation
• Interleukin-1beta (biosynthesis)
• Interleukin-6 (biosynthesis)
• NF-kappa B p50 Subunit (biosynthesis)
• RNA, Messenger (metabolism)
• Rats
• Rats, Sprague-Dawley
• Receptors, Aryl Hydrocarbon (metabolism)
• Resveratrol (pharmacology)